Jun. 1, 2020
Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress
First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100.